Effects of clopidogrel on soluble CD40 ligand and on high-sensitivity C-reactive protein in patients with stable coronary artery disease

American Heart Journal

Volumn 151, Issue 2, 2006, Pages 521.e1-521.e4

  Azar, Rabih R ^a   Kassab, Roland ^a   Zoghbi, Antoine ^a   Aboujaoudé, Simon ^a   El Osta, Hazem ^a   Ghorra, Pierre ^a   Germanos, Mirna ^a   Salamé, Elie ^a  

^a SAINT JOSEPH UNIVERSITY   (Lebanon)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; C REACTIVE PROTEIN; CD40 LIGAND; CLOPIDOGREL; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; PRAVASTATIN; SIMVASTATIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MECHANISM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE AGGREGATION INHIBITION; TREATMENT OUTCOME;

EID: 31344437038     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2005.10.021     Document Type: Article

References (14)

1. S. Yusuf, F. Zhao, and S.R. Mehta Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation N Engl J Med 345 2001 494 502
2. R.R. Steinhubl, P.B. Berger, T. Mann III for the CREDO Investigators Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention JAMA 288 2002 2411 2420
3. Z. Xiao, and P. Theroux Clopidogrel inhibits platelet-leukocyte interactions and thrombin receptor agonist peptide-induced platelet activation in patients with acute coronary syndrome J Am Coll Cardiol 43 2004 1982 1988
4. V. Henn, S. Steinbach, and K. Buchner The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40 Blood 98 2001 1047 1054
5. P. Andre, K.S. Prasad, and C.V. Denis CD40L stabilizes arterial thrombi by a beta-3 integrin-dependent mechanism Nat Med 8 2002 247 252
6. V. Henn, J. Slupsky, and M. Grafe CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells Nature 391 1998 591 594
7. C. Heeschen, S. Dimmeler, C.W. Hamm for the CAPTURE Study Investigators Soluble CD40 ligand in acute coronary syndromes N Engl J Med 348 2003 1104 1111
8. G. Liuzzo, L.M. Biasucci, and R. Gallimore The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina N Engl J Med 331 1994 417 424
9. U. Schonbeck, N. Varo, and P. Libby Soluble CD40L and cardiovascular risk in women Circulation 104 2001 2266 2268
10. P.M. Ridker, M. Cushman, and M.J. Stampfer Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men N Engl J Med 336 1997 973 979
11. F. Cipollone, A. Mezzetti, and E. Porreca Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia. Effects of statin therapy Circulation 106 2002 399 402
12. J.V. Mitsios, A.I. Papathanasiou, and F.I. Rodis Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes Circulation 109 2004 1335 1338
13. Blockade of the glycoprotein IIb/IIIa receptor to Avoid Vascular Occlusion Trial Investigators Randomized, double-blind, placebo-controlled international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease Circulation 108 2003 399 406
14. S.C. Zondlo, X. Wang, and G.Z. Feuorstein Effects of orally active glycoprotein IIb/IIIa antagonists on platelet CD40 ligand (CD 154) expression and platelet-heteroaggregate formation Thromb Res 106 2002 35 40